HIV-1 drug resistance genotypic profiles in children with undetectable plasma viremia during antiretroviral therapy

Brazilian Journal of Infectious Diseases

Volumn 15, Issue 1, 2011, Pages 60-65

  de Angelis, Daniela Souza Araújo ^a   Tateno, Adriana Fumie ^a   Diaz, Ricardo Sobhie ^b   Succi, Regina Célia de Menezes ^b   Pannuti, Claudio Sergio ^a   Gouvea, Aida de Fátima Barbosa ^b   Machado, Daisy Maria ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antiretroviral resistance; Antiretroviral therapy; Children; HIV 1; Prolonged viral suppression

Indexed keywords

ABACAVIR; AMPRENAVIR; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; RNA; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADOLESCENT; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GENE MUTATION; GENE REPRESSION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIMIT OF DETECTION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRESCHOOL CHILD; PROMOTER REGION; REVERSE TRANSCRIPTION; VIREMIA; VIRUS LOAD;

EID: 79955955069     PISSN: 14138670     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1413-8670(11)70141-6     Document Type: Article

References (24)

1. de la Rosa R., Ruiz-Mateos E., Rubio A., et al. Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy. J Antimicrob Chemother 2004, 53(1):95-101.
2. Palella F.J., Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338(13):853-860.
3. Saitoh A., Hsia K., Fenton T., et al. Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children. J Infect Dis 2002, 185(10):1409-1416.
4. Hermankova M., Ray S.C., Ruff C., et al. HIV-1 drug resistance profiles in children and adults with viral load of < 50 copies/mL receiving combination therapy. JAMA 2001, 286(2):196-207.
5. Izopet J., Sailler L., Sandres K., et al. Intermittent selection pressure with zidovudine plus zalcitabine treatment reduces the emergence in vivo of zidovudine resistance HIV mutations. J Med Virol 1999, 57(2):163-168.
6. Persaud D., Pierson T., Ruff C., et al. A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children. J Clin Invest 2000, 105(7):995-1003.
7. Resino S., Larru B., Maria Bellon J., et al. Effects of highly active antiretroviral therapy with nelfinavir in vertically HIV-1 infected children: 3 years of follow-up. Long-term response to nelfinavir in children. BMC Infect Dis 2006, 6:107.
8. De Rossi A. Virological and immunological response to antiretroviral therapy in HIV-1 infected children: genotypic and phenotypic assays in monitoring virological failure. New Microbiol 2004, 27(2 Suppl1):45-50.
9. Hermione Lyall E.G. Paediatric HIV in 2002--a treatable and preventable infection. J Clin Virol 2002, 25(2):107-119.
10. Gavin P.J., Yogev R. The role of protease inhibitor therapy in children with HIV infection. Paediatr Drugs 2002, 4(9):581-607.
11. Bailey J.R., Sedaghat A.R., Kieffer T., et al. Residual Human Immunodeficiency Virus Type 1 Viremia in Some Patients on Antiretroviral Therapy Is Dominated by a Small Number of Invariant Clones Rarely Found in Circulating CD4 T Cells. J Virol 2006, 80(13):6441-6457.
12. Ruff C.T., Ray S.C., Kwon P., et al. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol 2002, 76(18):9481-9492.
13. Lambotte O., Chaix M.L., Gubler B., et al. The lymphocyte HIV reservoir in patients on long-term HAART is a memory of virus evolution. AIDS 2004, 18(8):1147-1158.
14. Zanchetta M., Walker S., Burighel N., et al. Long-term decay of the HIV-1 reservoir in HIV-1-infected children treated with Highly Active Antiretroviral Therapy. J Infect Dis 2006, 193:1718-1726.
15. Matthews T., Salgo M., Greenberg M., et al. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 2004, 3(3):215-225.
16. Iglesias-Ussel M.D., Casado C., Yuste E., Olivares I., Lopez- Galindez C. In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants. J Gen Virol 2002, 83(Pt 1):93-101.
17. Sturmer M., Berger A., Preiser W. HIV-1 genotyping: comparison of two commercially available assays. Expert Rev Mol Diagn 2004, 4(3):281-291.
18. Zhang L., Ramratnam B., Tenner-Racz K., et al. Quantifying residual HIV-1 replication in patients receiving combination anti-retroviral therapy. N Engl J Med 1999, 340(21):1605-1613.
19. Starr S.E., Fletcher C.V., Spector A.S., et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency vírus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med 1999, 341(25):1874-1881.
20. Van Rossum A.M., Fraaij P.L., de Groot R. Efficacy of highly active anti-retroviral therapy in HIV-1 infected children. Lancet Infect Dis 2002, 2(2):93-102.
21. Cohen Stuart J.W., Wensing A.M., Kovacs C., et al. Transient relapses (" blips" ) of plasma HIV RNA levels during HAART are associated with drug resistance. J Acquir Immune Defic Syndr 2001, 28(2):105-113.
22. Naeger L.K., Struble K.A. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients. AIDS 2006, 20(6):847-853.
23. Lucas G.M. Anti-retroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven. J Antimicrob Chemother 2005, 55(4):413-416.
24. Ghosn J., Pellegrin I., Goujard C., et al. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 2006, 20(2):159-170.